Metal-free Oxidative Coupling of Amines with Sodium Sulfinates: A Mild Access to Sulfonamides

Electronic Supplementary Material (ESI) for RSC Advances. This journal is The Royal Society of Chemistry 2014 Supporting information for Metal-free Oxidative Coupling of Amines with Sodium Sulfinates: A Mild Access to Sulfonamides Jinwu Zhao,* Jingxiu Xu, Jiaxi Chen, Xiaoqin Wang and Minghua He School of Pharmacy, Guangdong Medical College, Dongguan 523808, China Table of Contents 1. General information... s2 2. Experimental procedure for the coupling of amines and sodium sulfinates... s2 3. Characterization data for products... s2 4. References... s6 5. Copies of product NMR spectra... s7 s1

1. General information 1 H and 13 C NMR spectra were recorded on a Bruker DRX-400 spectrometer; CDCl 3 was used as solvent and TMS as an internal standard. Mass spectra were recorded on a Finnigan Trace DSQ GC/MS spectrometer at an ionization voltage of 70 ev and equipped with a DB-WAX capillary column (internal diameter = 0.25 mm, length = 30 m). High resolution mass spectra were recorded with a Thermo MAT95XP (EI) mass spectrometer. 2. Experimental procedure for the coupling of amines and sodium sulfinates A 20 ml round-bottomed flask was charged with a magnetic stir-bar, sodium sulfinate 1 (1 mmol) and 0.5 ml water. After the solid dissolved completely, TBAI (20 mol%), TBHP (3.0 equiv), amine 2 (1.5 mmol) and 1.5 ml acetonitrile were added. The reaction mixture was stirred magnetically at 50 o C for 8h. When the reaction was finished, the solvent was removed in vacuo, and the residue was purified by flash column (petroleum ether/ethyl acetate) 3. Characterization data for products 4-tosylmorpholine (3aa) 1 1 H NMR (400 MHz, CDCl 3) δ 7.64 (d, J = 8.2 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 3.85 3.58 (m, 2H), 3.16 2.91 (m, 2H), 2.45 (s, 2H). 13 C NMR (101 MHz, CDCl 3) δ 143.9, 132.1, 129.7, 127.9, 66.1, 46.0, 21.5. MS (EI, 70 ev) m/z (%): 241(M + ), 198, 155, 106, 91, 77. N,4-dimethylbenzenesulfonamide (3ab) 1 1 H NMR (400 MHz, CDCl 3) δ 7.75 (d, J = 8.0 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 4.81 (d, J = 5.6 Hz, 1H), 2.62 (d, J = 5.3 Hz, 3H), 2.42 (s, 3H). 13 C NMR (101 MHz, CDCl 3) δ 143.4, 135.73, 129.7, 127.2, 29.2, 21.5. MS (EI, 70 ev) m/z (%): 185(M + ), 155, 121, 91, 77. N-butyl-4-methylbenzenesulfonamide (3ac) 1. 1 H NMR (400 MHz, CDCl 3) δ 7.76 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 7.4 Hz, 2H), 4.77 (s, 1H), 2.93 (dd, J = 6.8, 2.1 Hz, 2H), 2.43 (s, 3H), 1.50 1.36 (m, 2H), 1.34 1.23 (m, 2H), 0.84 (t, J = 7.3 Hz, 3H). 13 C NMR (101 MHz, CDCl 3) δ 143.3, 137.1, 129.7, 127.1, 42.9, 31.6, 21.5, 19.7, 13.5. MS (EI, 70 ev) m/z (%): 227(M + ), 184, 155, 91, 77. N-sec-butyl-4-methylbenzenesulfonamide (3ad) 1 1 H NMR (400 MHz, CDCl 3) δ 7.71 (d, J = 8.1 Hz, 2H), 7.22 (d, J = 7.9 Hz, 2H), 4.66 (d, J = 8.0 Hz, 1H), 3.22 3.10 (m, 1H), 2.35 (s, 3H), 1.38 1.26 (m, 2H), 0.94 (d, J = 6.6 Hz, 3H), 0.72 (t, J = 7.5 Hz, 3H). 13 C NMR (101 MHz, CDCl 3) δ 143.1, 138.4, 129.6, 127.1, 51.4, 30.3, 21.5, 21.1, 9.9. MS (EI, 70 ev) m/z (%): 227 (M + ), 198, 155, 91, 77. s2

N-tert-butyl-4-methylbenzenesulfonamide (3ae) 1 1 H NMR (400 MHz, CDCl 3) δ 7.79 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 7.5 Hz, 2H), 4.84 (s, 1H), 2.42 (s, 3H), 1.22 (s, 9H). 13 C NMR (101 MHz, CDCl 3) δ 142.8, 140.6, 129.5, 127.0, 54.6, 30.2, 21.5. MS (EI, 70 ev) m/z (%): 227 (M + ), 212, 155, 91, 77. N-benzyl-4-methylbenzenesulfonamide(3af) 1 1 H NMR (400 MHz, CDCl 3) δ 7.76 (d, J = 8.0 Hz, 2H), 7.37 7.12 (m, 8H), 5.09 (s, 1H), 4.12 (d, J = 5.6 Hz, 2H), 2.44 (s, 3H). 13 C NMR (101 MHz, CDCl 3) δ 143.5, 137.0, 136.4, 129.8, 128.7, 127.9, 127.8, 127.2, 47.3, 21.6. MS (EI, 70 ev) m/z (%): 261 (M + ), 209, 176, 155, 106, 79. N-allyl-4-methylbenzenesulfonamide (3ag) 1 1 H NMR (400 MHz, CDCl 3) δ 7.76 (d, J = 7.8 Hz, 2H), 7.31 (d, J = 7.7 Hz, 2H), 5.73 (ddt, J = 16.3, 10.9, 5.7 Hz, 1H), 5.13 (dd, J = 28.2, 13.6 Hz, 2H), 4.62 (s, 1H), 3.59 (s, 2H), 2.43 (s, 3H). 13 C NMR (101 MHz, CDCl 3) δ 143.6, 137.1, 133.1, 129.8, 127.2, 117.8, 45.8, 21.6. MS (EI, 70 ev) m/z (%): 211(M + ), 184, 155, 91, 77. N,N,4-trimethylbenzenesulfonamide(3ah) 1 1 H NMR (400 MHz, CDCl 3) δ 7.67 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 7.9 Hz, 2H), 2.69 (s, 6H), 2.44 (s, 3H). 13 C NMR (101 MHz, CDCl 3) δ 143.5, 132.5, 129.6, 127.8, 38.0, 21.5. MS (EI, 70 ev) m/z (%): 199(M + ), 184, 155, 91, 77. N,N-diethyl-4-methylbenzenesulfonamide (3ai) 1 1 H NMR (400 MHz, CDCl 3) δ 7.69 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 2.4 Hz, 2H), 3.22 (q, J = 7.1 Hz, 4H), 2.41 (s, 3H), 1.12 (t, J = 7.1 Hz, 6H). 13 C NMR (101 MHz, CDCl 3) δ 142.8, 137.4, 129.5, 127.0, 42.0, 21.4, 14.1. MS (EI, 70 ev) m/z (%): 227(M + ), 184, 155, 91, 77. N,N-diisobutyl-4-methylbenzenesulfonamide(3aj) 1. 1 H NMR (400 MHz, CDCl 3) δ 7.68 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 2.85 (d, J = 7.5 Hz, 4H), 2.42 (s, 3H), 1.97 1.81 (m, 2H), 0.90 (s, 7H), 0.88 (s, 7H). 13 C NMR (101 MHz, CDCl 3) δ 142.8, 136.7, 129.407, 127.3, 57.2, 27.3, 21.4, 20.2. MS (EI, 70 ev) m/z (%): 283(M + ), 240, 184, 155, 91, 77. s3

1-tosylpyrrolidine (3ak) 1 1 H NMR (400 MHz, CDCl 3) δ 7.72 (dd, J = 8.2, 2.4 Hz, 2H), 7.32 (d, J = 7.9 Hz, 2H), 3.24 (t, J = 6.7 Hz, 4H), 2.43 (s, 3H), 1.75 (t, J = 6.8 Hz, 4H). 13 C NMR (101 MHz, CDCl 3) δ 143.3, 134.0, 129.6, 127.6, 47.9, 25.2, 21.5. MS (EI, 70 ev) m/z (%): 225(M + ), 155, 91, 77. N-benzyl-N,4-dimethylbenzenesulfonamide (3al) 1 1 H NMR (400 MHz, CDCl 3) δ 7.72 (d, J = 8.2 Hz, 2H), 7.39 7.26 (m, 7H), 4.12 (s, 2H), 2.58 (s, 3H), 2.45 (s, 3H). 13 C NMR (101 MHz, CDCl 3) δ 143.4, 135.7, 134.4, 129.7, 128.6, 128.3, 127.8, 127.5, 54.1, 34.3, 21.5. 4-methyl-N-phenylbenzenesulfonamide(3am) 1 1 H NMR (400 MHz, CDCl 3) δ 7.91 7.54 (m, 3H), 7.42 6.85 (m, 7H), 2.31 (s, 3H). 13 C NMR (101 MHz, CDCl 3) δ 143.8, 136.7, 136.0, 129.6, 129.2, 127.3, 125.1, 121.3, 21.5. MS (EI, 70 ev) m/z (%): 247(M + ), 182, 155, 91, 77. N,4-dimethyl-N-phenylbenzenesulfonamide(3an) 1 1 H NMR (400 MHz, CDCl 3) δ 7.42 (d, J = 8.4 Hz, 2H), 7.33 7.16 (m, 6H), 7.14 7.04 (m, 2H), 3.16 (s, 3H), 2.41 (s, 3H). 13 C NMR (101 MHz, CDCl 3) δ 143.5, 141.6, 133.6, 129.3, 128.8, 127.9, 127.2, 126.6, 38.0, 21.5. MS (EI, 70 ev) m/z (%): 261(M + ), 197, 155, 106, 91, 77. 1-tosylindoline (3ao) 1 1 H NMR (400 MHz, CDCl 3) δ 7.72 (dd, J = 8.2, 2.4 Hz, 2H), 7.32 (d, J = 7.9 Hz, 2H), 3.24 (t, J = 6.7 Hz, 4H), 2.43 (s, 3H), 1.75 (t, J = 6.8 Hz, 4H). 13 C NMR (101 MHz, CDCl 3) δ 143.3, 134.0, 129.6, 127.6, 47.9, 25.2, 21.5. MS (EI, 70 ev) m/z (%): 273(M + ), 226, 118, 91, 77. N-(2-hydroxypropyl)-4-methylbenzenesulfonamide (3ap) 1 1 H NMR (400 MHz, CDCl 3) δ 7.75 (d, J = 8.0 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 5.27 (s, 1H), 3.95 3.85 (m, 1H), 3.03 2.95 (m, 1H), 2.84 2.67 (m, 1H), 2.43 (s, 3H), 2.29 (s, 1H), 1.15 (d, J = 6.3 Hz, 3H). 13 C NMR (101 MHz, CDCl 3) δ 143.6, 136.8, 129.8, 127.1, 66.6, 50.1, 21.6, 20.6. MS (EI, 70 ev) m/z (%): 229(M + ), 198, 155, 91, 77. s4

N-(2-hydroxyethyl)-N,4-dimethylbenzenesulfonamide(3aq) 1 1 H NMR (400 MHz, CDCl 3) δ 7.73 7.65 (m, 2H), 7.34 (d, J = 8.0 Hz, 2H), 3.77 (t, J = 5.3 Hz, 2H), 3.16 (t, J = 5.3 Hz, 2H), 2.83 (s, 3H), 2.44 (s, 3H). 13 C NMR (101 MHz, CDCl 3) δ 143.7, 134.3, 129.8, 127.5, 60.4, 52.6, 36.2, 21.6. MS (EI, 70 ev) m/z (%): 229(M + ), 198, 155, 91, 77. N-ethyl-N-(4-hydroxybutyl)-4-methylbenzenesulfonamide (3ar) 1 H NMR (400 MHz, CDCl 3) δ 7.69 (d, J = 8.3 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 3.66 (t, J = 6.1 Hz, 2H), 3.36 2.92 (m, 4H), 2.42 (s, 3H), 1.85 (s, 1H), 1.70 1.49 (m, 4H), 1.10 (t, J = 7.2 Hz, 3H). 13 C NMR (101 MHz, CDCl 3) δ 143.0, 137.1, 129.6, 127.0, 62.3, 47.3, 42.7, 29.6, 25.2, 21.5, 14.0. M S (EI, 70 ev) m/z (%): 271(M + ), 240, 155, 91, 77. HRMS (EI) m/z: calcd for: C 13H 21NO 3S (M) + 271.1242, Found: 271.1238. 4-(naphthalen-2-ylsulfonyl)morpholine (3ba) 2 1 H NMR (400 MHz, CDCl 3) δ 8.34 (s, 1H), 7.97 (d, J = 8.4 Hz, 2H), 7.90 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 8.7 Hz, 1H), 7.61 (p, J = 7.1 Hz, 2H), 3.71 (t, J = 4.7 Hz, 4H), 3.05 (t, J = 4.6 Hz, 4H). 13 C NMR (101 MHz, CDCl 3) δ 134.9, 132.3, 132.2, 129.3, 129.2, 129.0, 128.0, 127.7, 123.0, 66.1, 46.1. M S (EI, 70 ev) m/z (%): 277(M + ), 191, 127, 86, 56. 4-((4-chlorophenyl)sulfonyl)morpholine (3ca) 3 1 H NMR (400 MHz, CDCl 3) δ 7.62 (dd, J = 66.7, 8.3 Hz, 1H), 3.72 (t, J = 4.6 Hz, 1H), 2.99 (t, J = 4.5 Hz, 1H). 13 C NMR (101 MHz, CDCl 3) δ 139.5, 133.7, 129.5, 129.2, 66.0, 45.9. M S (EI, 70 ev) m/z (%): 261(M + ), 218, 175, 111, 86, 75, 56. 4-((4-methoxyphenyl)sulfonyl)morpholine (3da) 4 1 H NMR (400 MHz, CDCl 3) δ 7.76 7.60 (m, 2H), 7.11 6.91 (m, 21H), 3.88 (s, 1H), 3.73 (t, J = 4.8 Hz, 4H), 2.97 (t, J = 4.7 Hz, 4H). 13 C NMR (101 MHz, CDCl 3) δ 163.2, 130.0, 126.6, 114.3, 66.1, 55.7, 46.0. M S (EI, 70 ev) m/z (%): 257(M + ), 171, 122, 107, 86, 77, 56. 4-((4-(trifluoromethyl)phenyl)sulfonyl)morpholine (3ea) 1 H NMR (400 MHz, CDCl 3) δ 7.90 (d, J = 8.2 Hz, 2H), 7.84 (d, J = 8.2 Hz, 2H), 3.75 (t, J = 4.7 Hz, 4H), 3.04 (t, J = 4.7 Hz, 4H). 13 C NMR s5

(101 MHz, CDCl 3) δ 139.0, 135.2, 134.9, 134.5, 134.2, 128.3, 126.4, 126.3, 126.3, 126.3, 124.5, 121.8, 119.1, 66.0, 45.9. M S (EI, 70 ev) m/z (%): 295(M + ), 252, 209, 145, 86, 56. HRMS (EI) m/z: calcd for: C 11H 12F 3NO 3S(M) + 295.0490, Found: 295.0492. 4-(methylsulfonyl)morpholine (3fa) 1 1 H NMR (400 MHz, CDCl 3) δ 3.87 3.69 (m, 4H), 3.34 3.13 (m, 4H), 2.79 (s, 3H). 13 C NMR (101 MHz, CDCl 3) δ 66.3, 45.8, 34.0. MS (EI, 70 ev) m/z (%): 165(M + ), 122, 107, 86. 4-(ethylsulfonyl)morpholine (3ga) 1 1 H NMR (400 MHz, CDCl 3) δ 3.90 3.57 (m, 4H), 3.54 3.16 (m, 4H), 2.97 (q, J = 7.4 Hz, 2H), 1.39 (t, J = 7.4 Hz, 3H). 13 C NMR (101 MHz, CDCl 3) δ 66.6, 45.9, 43.5, 7.7. MS (EI, 70 ev) m/z (%): 179(M + ), 148, 136, 86. 4-(cyclopropylsulfonyl)morpholine (3ha) 1 1 H NMR (400 MHz, CDCl 3) δ 3.93 3.63 (m, 4H), 3.50 3.14 (m, 4H), 2.27 (ddd, J = 12.8, 8.1, 4.8 Hz, 1H), 1.22 1.11 (m, 2H), 1.06 0.94 (m, 2H). 13 C NMR (101 MHz, CDCl 3) δ 66.4, 46.2, 25.0, 4.2. MS (EI, 70 ev) m/z (%): 191(M + ), 160, 148, 105, 86. 4. References (1) X. Tang, L. Huang, C. Qi, X. Wu, W. Wu and H. Jiang, Chem. Commun., 2013, 49, 6102. (2) R. R. Naredla and D. A. Klumpp, Tetrahedron Lett., 2013, 54, 5945 (3) X. Huang, J. Wang, Z. Ni, S. Wang and Y. Pan, Chem. Commun., 2014, 35, 4582 (4) J. R. DeBergh, N. Niljianskul, and S. L. Buchwald, J. Am. Chem. Soc., 2013, 135, 10638. s6

5. Copies of product NMR spectra s7

s8

s9

s10

s11

s12

s13

s14

s15

s16

s17

s18

s19

s20

s21

s22

s23

s24

s25

s26

s27

s28

s29

s30

s31